{
  "success": true,
  "pagesUsed": [
    8,
    9,
    10
  ],
  "modelUsed": "gemini-3-flash-preview",
  "objectivesEndpoints": {
    "objectives": [
      {
        "id": "obj_1",
        "name": "Primary Efficacy Objective",
        "text": "To demonstrate that 3 mg LY900018 is non-inferior to 1 mg IMG for the proportion of patients achieving treatment success from insulin-induced hypoglycemia using a non-inferiority margin of 10%",
        "level": {
          "code": "C85826",
          "codeSystem": "http://www.cdisc.org",
          "codeSystemVersion": "2024-09-27",
          "decode": "Trial Primary Objective",
          "instanceType": "Code"
        },
        "endpointIds": [
          "ep_1"
        ],
        "instanceType": "Objective"
      },
      {
        "id": "obj_2",
        "name": "Secondary Safety Objective",
        "text": "To compare the safety and tolerability of 3 mg LY900018 with 1 mg IMG",
        "level": {
          "code": "C85827",
          "codeSystem": "http://www.cdisc.org",
          "codeSystemVersion": "2024-09-27",
          "decode": "Trial Secondary Objective",
          "instanceType": "Code"
        },
        "endpointIds": [
          "ep_2"
        ],
        "instanceType": "Objective"
      },
      {
        "id": "obj_3",
        "name": "Secondary Pharmacokinetic Objective",
        "text": "To characterize the PK profile of 3 mg LY900018 compared to 1 mg IMG",
        "level": {
          "code": "C85827",
          "codeSystem": "http://www.cdisc.org",
          "codeSystemVersion": "2024-09-27",
          "decode": "Trial Secondary Objective",
          "instanceType": "Code"
        },
        "endpointIds": [
          "ep_3"
        ],
        "instanceType": "Objective"
      },
      {
        "id": "obj_4",
        "name": "Secondary Pharmacodynamic Objective",
        "text": "To characterize the PD profile of 3 mg LY900018 compared to 1 mg IMG",
        "level": {
          "code": "C85827",
          "codeSystem": "http://www.cdisc.org",
          "codeSystemVersion": "2024-09-27",
          "decode": "Trial Secondary Objective",
          "instanceType": "Code"
        },
        "endpointIds": [
          "ep_4"
        ],
        "instanceType": "Objective"
      }
    ],
    "endpoints": [
      {
        "id": "ep_1",
        "name": "Primary Efficacy Endpoint",
        "text": "The proportion of patients achieving treatment success defined as either an increase in PG to >70 mg/dL or an increase of >20 mg/dL from nadir within 30 minutes after administration of glucagon. The nadir is defined as the minimum PG value at the time of or within 10 minutes following glucagon administration.",
        "level": {
          "code": "C98772",
          "codeSystem": "http://www.cdisc.org",
          "codeSystemVersion": "2024-09-27",
          "decode": "Primary Outcome Measure",
          "instanceType": "Code"
        },
        "instanceType": "Endpoint",
        "purpose": "Efficacy"
      },
      {
        "id": "ep_2",
        "name": "Safety and Tolerability Endpoints",
        "text": "SAE, TEAEs (including gastrointestinal, nasal, and non-nasal AEs), vital signs",
        "level": {
          "code": "C98781",
          "codeSystem": "http://www.cdisc.org",
          "codeSystemVersion": "2024-09-27",
          "decode": "Secondary Outcome Measure",
          "instanceType": "Code"
        },
        "instanceType": "Endpoint",
        "purpose": "Safety"
      },
      {
        "id": "ep_3",
        "name": "Pharmacokinetic Endpoints",
        "text": "PK parameters include AUC, Cmax, Tmax",
        "level": {
          "code": "C98781",
          "codeSystem": "http://www.cdisc.org",
          "codeSystemVersion": "2024-09-27",
          "decode": "Secondary Outcome Measure",
          "instanceType": "Code"
        },
        "instanceType": "Endpoint",
        "purpose": "Pharmacokinetic"
      },
      {
        "id": "ep_4",
        "name": "Pharmacodynamic Endpoints",
        "text": "PD parameters include BGmax and Tmax",
        "level": {
          "code": "C98781",
          "codeSystem": "http://www.cdisc.org",
          "codeSystemVersion": "2024-09-27",
          "decode": "Secondary Outcome Measure",
          "instanceType": "Code"
        },
        "instanceType": "Endpoint",
        "purpose": "Pharmacodynamic"
      }
    ],
    "estimands": [
      {
        "id": "est_1",
        "name": "Primary Efficacy Estimand",
        "populationSummary": "Japanese patients with Type 1 or Type 2 Diabetes Mellitus (ITT population) Summary measure: Difference in proportions (IMG - LY900018) with 95% Confidence Interval.",
        "analysisPopulationId": "est_1_pop",
        "variableOfInterestId": "ep_1",
        "interventionIds": [
          "est_1_int"
        ],
        "intercurrentEvents": [
          {
            "id": "ice_1",
            "name": "Use of rescue medication",
            "text": "Patient receiving additional treatments to increase plasma glucose before achieving success",
            "strategy": "Composite",
            "instanceType": "IntercurrentEvent"
          },
          {
            "id": "ice_2",
            "name": "Treatment discontinuation",
            "text": "Patient discontinues the study or fails to complete both treatment periods",
            "strategy": "Treatment Policy",
            "instanceType": "IntercurrentEvent"
          }
        ],
        "instanceType": "Estimand",
        "treatment": "3 mg Nasal Glucagon (LY900018) vs 1 mg Intramuscular Glucagon (IMG)",
        "analysisPopulation": "Japanese patients with Type 1 or Type 2 Diabetes Mellitus (ITT population)",
        "variableOfInterest": "Proportion of patients achieving treatment success (PG >70 mg/dL or increase ≥20 mg/dL from nadir within 30 minutes)",
        "summaryMeasure": "Difference in proportions (IMG - LY900018) with 95% Confidence Interval"
      },
      {
        "id": "est_2",
        "name": "Safety Estimand",
        "populationSummary": "Japanese patients with Type 1 or Type 2 Diabetes Mellitus who received at least one dose of study drug Summary measure: Risk difference or frequency distribution.",
        "analysisPopulationId": "est_2_pop",
        "variableOfInterestId": "ep_2",
        "interventionIds": [
          "est_2_int"
        ],
        "intercurrentEvents": [
          {
            "id": "ice_3",
            "name": "Treatment discontinuation",
            "text": "Discontinuation of study drug due to an adverse event",
            "strategy": "While on Treatment",
            "instanceType": "IntercurrentEvent"
          }
        ],
        "instanceType": "Estimand",
        "treatment": "3 mg Nasal Glucagon (LY900018) vs 1 mg Intramuscular Glucagon (IMG)",
        "analysisPopulation": "Japanese patients with Type 1 or Type 2 Diabetes Mellitus who received at least one dose of study drug",
        "variableOfInterest": "Incidence of SAEs, TEAEs, and changes in vital signs",
        "summaryMeasure": "Risk difference or frequency distribution"
      }
    ],
    "summary": {
      "primaryObjectives": 1,
      "secondaryObjectives": 3,
      "exploratoryObjectives": 0,
      "totalEndpoints": 4,
      "totalEstimands": 2
    }
  },
  "rawResponse": {
    "objectives": [
      {
        "id": "obj_1",
        "name": "Primary Efficacy Objective",
        "text": "To demonstrate that 3 mg LY900018 is non-inferior to 1 mg IMG for the proportion of patients achieving treatment success from insulin-induced hypoglycemia using a non-inferiority margin of 10%",
        "level": {
          "code": "C85826",
          "codeSystem": "http://www.cdisc.org",
          "codeSystemVersion": "2024-09-27",
          "decode": "Trial Primary Objective",
          "instanceType": "Code"
        },
        "endpointIds": [
          "ep_1"
        ],
        "instanceType": "Objective"
      },
      {
        "id": "obj_2",
        "name": "Secondary Safety Objective",
        "text": "To compare the safety and tolerability of 3 mg LY900018 with 1 mg IMG",
        "level": {
          "code": "C85827",
          "codeSystem": "http://www.cdisc.org",
          "codeSystemVersion": "2024-09-27",
          "decode": "Trial Secondary Objective",
          "instanceType": "Code"
        },
        "endpointIds": [
          "ep_2"
        ],
        "instanceType": "Objective"
      },
      {
        "id": "obj_3",
        "name": "Secondary Pharmacokinetic Objective",
        "text": "To characterize the PK profile of 3 mg LY900018 compared to 1 mg IMG",
        "level": {
          "code": "C85827",
          "codeSystem": "http://www.cdisc.org",
          "codeSystemVersion": "2024-09-27",
          "decode": "Trial Secondary Objective",
          "instanceType": "Code"
        },
        "endpointIds": [
          "ep_3"
        ],
        "instanceType": "Objective"
      },
      {
        "id": "obj_4",
        "name": "Secondary Pharmacodynamic Objective",
        "text": "To characterize the PD profile of 3 mg LY900018 compared to 1 mg IMG",
        "level": {
          "code": "C85827",
          "codeSystem": "http://www.cdisc.org",
          "codeSystemVersion": "2024-09-27",
          "decode": "Trial Secondary Objective",
          "instanceType": "Code"
        },
        "endpointIds": [
          "ep_4"
        ],
        "instanceType": "Objective"
      }
    ],
    "endpoints": [
      {
        "id": "ep_1",
        "name": "Primary Efficacy Endpoint",
        "text": "The proportion of patients achieving treatment success defined as either an increase in PG to >70 mg/dL or an increase of >20 mg/dL from nadir within 30 minutes after administration of glucagon. The nadir is defined as the minimum PG value at the time of or within 10 minutes following glucagon administration.",
        "level": {
          "code": "C98772",
          "codeSystem": "http://www.cdisc.org",
          "codeSystemVersion": "2024-09-27",
          "decode": "Primary Outcome Measure",
          "instanceType": "Code"
        },
        "instanceType": "Endpoint",
        "purpose": "Efficacy"
      },
      {
        "id": "ep_2",
        "name": "Safety and Tolerability Endpoints",
        "text": "SAE, TEAEs (including gastrointestinal, nasal, and non-nasal AEs), vital signs",
        "level": {
          "code": "C98781",
          "codeSystem": "http://www.cdisc.org",
          "codeSystemVersion": "2024-09-27",
          "decode": "Secondary Outcome Measure",
          "instanceType": "Code"
        },
        "instanceType": "Endpoint",
        "purpose": "Safety"
      },
      {
        "id": "ep_3",
        "name": "Pharmacokinetic Endpoints",
        "text": "PK parameters include AUC, Cmax, Tmax",
        "level": {
          "code": "C98781",
          "codeSystem": "http://www.cdisc.org",
          "codeSystemVersion": "2024-09-27",
          "decode": "Secondary Outcome Measure",
          "instanceType": "Code"
        },
        "instanceType": "Endpoint",
        "purpose": "Pharmacokinetic"
      },
      {
        "id": "ep_4",
        "name": "Pharmacodynamic Endpoints",
        "text": "PD parameters include BGmax and Tmax",
        "level": {
          "code": "C98781",
          "codeSystem": "http://www.cdisc.org",
          "codeSystemVersion": "2024-09-27",
          "decode": "Secondary Outcome Measure",
          "instanceType": "Code"
        },
        "instanceType": "Endpoint",
        "purpose": "Pharmacodynamic"
      }
    ],
    "estimands": [
      {
        "id": "est_1",
        "name": "Primary Efficacy Estimand",
        "populationSummary": "Japanese patients with Type 1 or Type 2 Diabetes Mellitus (ITT population) Summary measure: Difference in proportions (IMG - LY900018) with 95% Confidence Interval.",
        "analysisPopulationId": "est_1_pop",
        "variableOfInterestId": "ep_1",
        "interventionIds": [
          "est_1_int"
        ],
        "intercurrentEvents": [
          {
            "id": "ice_1",
            "name": "Use of rescue medication",
            "text": "Patient receiving additional treatments to increase plasma glucose before achieving success",
            "strategy": "Composite",
            "instanceType": "IntercurrentEvent"
          },
          {
            "id": "ice_2",
            "name": "Treatment discontinuation",
            "text": "Patient discontinues the study or fails to complete both treatment periods",
            "strategy": "Treatment Policy",
            "instanceType": "IntercurrentEvent"
          }
        ],
        "instanceType": "Estimand",
        "treatment": "3 mg Nasal Glucagon (LY900018) vs 1 mg Intramuscular Glucagon (IMG)",
        "analysisPopulation": "Japanese patients with Type 1 or Type 2 Diabetes Mellitus (ITT population)",
        "variableOfInterest": "Proportion of patients achieving treatment success (PG >70 mg/dL or increase ≥20 mg/dL from nadir within 30 minutes)",
        "summaryMeasure": "Difference in proportions (IMG - LY900018) with 95% Confidence Interval"
      },
      {
        "id": "est_2",
        "name": "Safety Estimand",
        "populationSummary": "Japanese patients with Type 1 or Type 2 Diabetes Mellitus who received at least one dose of study drug Summary measure: Risk difference or frequency distribution.",
        "analysisPopulationId": "est_2_pop",
        "variableOfInterestId": "ep_2",
        "interventionIds": [
          "est_2_int"
        ],
        "intercurrentEvents": [
          {
            "id": "ice_3",
            "name": "Treatment discontinuation",
            "text": "Discontinuation of study drug due to an adverse event",
            "strategy": "While on Treatment",
            "instanceType": "IntercurrentEvent"
          }
        ],
        "instanceType": "Estimand",
        "treatment": "3 mg Nasal Glucagon (LY900018) vs 1 mg Intramuscular Glucagon (IMG)",
        "analysisPopulation": "Japanese patients with Type 1 or Type 2 Diabetes Mellitus who received at least one dose of study drug",
        "variableOfInterest": "Incidence of SAEs, TEAEs, and changes in vital signs",
        "summaryMeasure": "Risk difference or frequency distribution"
      }
    ]
  }
}